3- (4- t- butylphenyl)- N- (2,3- dihydrobenzo(b)(1,4)dioxin- 6- yl)acrylamide

06/18/2020 - "Behavioral assessment using the paw withdrawal response showed that PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia after 14 days was significantly inhibited by oral or intrathecal administration of the TRPV1 antagonist AMG9810. "
04/01/2016 - "Intramuscular administration of the TRPV1 antagonist AMG-9810 partially reversed this mechanical hyperalgesia in masseter muscle. "
01/01/2016 - "Direct administration of C5a into the mouse hindpaw produced strong thermal hyperalgesia, an effect that was absent in TRPV1 knock-out mice, and was blocked by the TRPV1 antagonist AMG9810. "
01/01/2015 - "AMG9810 also suppressed mechanical hyperalgesia evoked by pharmacologic activation of PKC. "
03/01/2013 - "Importantly, the αβmeATP-induced hyperalgesia was prevented by pretreatment of the muscle with a TRPV1 antagonist, AMG9810. "

05/01/2011 - "In this study, we found that a typical TRPV1 antagonist, AMG9810, promotes mouse skin tumor development. "
05/01/2011 - "This increase was not only observed in AMG9810-treated tumor tissue but was also found in skin tissue treated with AMG9810. "
11/25/2020 - "Finally, in a recently developed xenograft model of systemic MM with BM involvement, bortezomib/AMG9810 treatment effectively reduced tumor burden in the BM of MM-bearing mice. "
09/15/2022 - "Intrathecal injection of AMG9810 (TRPV1 antagonist) reduced ongoing Ehrlich tumor-triggered mechanical and thermal hyperalgesia (p < 0.05). "
07/01/2017 - "Ca2+ chelators and the MCU inhibitor ruthenium 360, an MPTP opener atractyloside, capsazepine, and AMG9810 all decreased [Ca2+]mit and sensitized these tumor cells to TRAIL cytotoxicity. "

08/01/2017 - "Also, neurological deficits were decreased by AMG9810 seven days after cerebral ischemia. "
08/01/2017 - "In this study, the effects of TRPV1 agonist (capsaicin) and antagonist (AMG9810) on cerebral ischemia were investigated. "

12/01/2013 - "In the present study, we have evaluated the effects of AMG9810 , a selective antagonist of TRPV1 receptors, on the motor and cognitive functions in a rat model of Parkinson's disease generated by an intracerebroventricular injection of 6- hydroxydopamine (6-OHDA) (200 μg per animal). "

12/11/2019 - "Ongoing pain from inflamed masseter muscle was also reduced in KI mice, and was further inhibited by the TRPV1 antagonist AMG9810. "
01/01/2019 - "Selective blockage of central TRPV1 channel activity by intrathecal administration of AMG9810 reversed the induced pain, and abolished the induced CBV increase in thalamocortical regions. "
01/01/2016 - "Furthermore, AMG-9810 could relieve orthodontic pain arising from experimental tooth movement in rats. "
10/01/2013 - "A major role for TRPV1 channels in pain-related behavior was indicated by the ability of a specific TRPV1 antagonist, AMG9810, to reverse SCI-induced hypersensitivity of hind limb withdrawal responses to mechanical and thermal stimuli at a dose that did not block detection of noxious heat. "
04/01/2012 - "Systemic AMG9810, a transient receptor potential V1 channel (TRPV1) antagonist, effectively blocked thermal hypersensitivity, but failed to block high-dose MIA-induced weight asymmetry or ongoing pain. "